Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 3.9% Higher – What’s Next?

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded up 3.9% during trading on Tuesday . The company traded as high as $3.48 and last traded at $3.48. 707,252 shares were traded during mid-day trading, a decline of 75% from the average session volume of 2,876,646 shares. The stock had previously closed at $3.35.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective for the company. Wells Fargo & Company lowered their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Up 4.3 %

The stock’s fifty day moving average is $4.15 and its 200 day moving average is $5.23. The company has a market capitalization of $587.31 million, a P/E ratio of -122.33 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 earnings per share. On average, analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.90% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC grew its position in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,345 shares during the period. KBC Group NV grew its position in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,198 shares during the period. GAMMA Investing LLC grew its position in shares of Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after buying an additional 8,156 shares during the period. First Dallas Securities Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth about $73,000. Finally, Diversified Trust Co purchased a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth about $52,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.